Floatz logo

Idarubicin

Childhood Acute Myeloid Leukemia

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversitySmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
95/ 100

Competitive context

45 Active assets in the Childhood Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Joanna Yi
Phase 3BBB
CYTARABINE
Children's Oncology Group
Phase 3BBB
FILGRASTIM
National Cancer Institute (NCI)
Phase 3BBB
METHOTREXATE
Children's Oncology Group
Phase 3BBB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

Idarubicin is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative · Phase 4
81 / 100
View asset →
acute myeloid leukemia with 11q23 abnormalitiesDormant
BBB
Indicative · Phase 2
76 / 100
View asset →
adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →